KYNB

Business Context and Reporting Period

Kyntra Bio, Inc. (formerly FibroGen, Inc.) is a biopharmaceutical company focused on oncology and rare disease therapies. The company rebranded in January 2026 and trades under the symbol "KYNB." This Form 10-Q covers the quarterly period ended June 30, 2026. The company's primary assets include the development of FG-3246 (an antibody-drug conjugate for prostate cancer) and roxadustat (for anemia in chronic kidney disease and myelodysplastic syndromes). Notably, the company sold its China operations to AstraZeneca in August 2025, which are now reported as discontinued operations.

Key Financial Metrics

Note: Revenue for the three months ended June 30, 2026, is negative due to a downward adjustment in estimated variable consideration related to API shipments under the Astellas Japan Agreement.

Material Changes vs. Prior Period

• Revenue Volatility: Total revenue for the three months ended June 30, 2026, decreased by 209% to $(1.5) million compared to $1.3 million in the prior year period. This was driven by a $2.9 million reduction in drug product revenue due to updated estimates of variable consideration for the Astellas Japan Agreement. For the six-month period, revenue decreased 45% to $2.3 million.
• Net Income Turnaround: The company reported a net income of $12.0 million for the quarter, a significant improvement from a net loss of $7.6 million in the same period last year. This is primarily attributable to a $30.9 million gain on the deconsolidation of its European subsidiary, FibroGen Europe, which filed for bankruptcy in April 2026.
• Operating Expenses: Total operating costs and expenses increased 20% to $16.1 million for the quarter. This increase was driven by a $3.5 million rise in legal expenses (related to indemnification for a former officer) and higher clinical trial costs for the FG-3246 Phase 2 program, partially offset by reductions in employee-related and facility expenses.
• Discontinued Operations: The sale of China operations (FibroGen International) to AstraZeneca was completed in August 2025. Consequently, results from these operations are classified as discontinued. The company received the final $4.0 million holdback payment in June 2026.

Guidance, Outlook, and Risks

• Clinical Pipeline: The company is actively enrolling in a Phase 2 monotherapy dose optimization study for FG-3246 in metastatic castration-resistant prostate cancer (mCRPC), with interim results expected in Q4 2026. For roxadustat, the company aims to initiate a Phase 3 trial for anemia in lower-risk myelodysplastic syndromes (MDS) in Q4 2026, following FDA Orphan Drug Designation in December 2025.
• Liquidity: Management believes existing cash and cash equivalents ($50.6 million) plus investments ($44.7 million) are sufficient to fund operations for at least 12 months. However, the company anticipates continued losses and may require additional financing.
• Debt Obligations: The company has a Revenue Interest Financing Agreement (RIFA) with NovaQuest, carrying a liability of approximately $70.7 million. The effective interest rate is 15.16%, with potential balloon payments due in 2029 and 2031 if revenue targets are not met.
• Nasdaq Compliance Risk: In April 2026, the company received notice of non-compliance with Nasdaq Global Select Market listing requirements regarding total assets and revenue due to the classification of China operations as discontinued. The company has submitted a compliance plan and may consider transferring to the Nasdaq Capital Market.
• Legal Contingencies: The company is obligated to indemnify a former officer in an ongoing SEC complaint, with accrued liabilities of approximately $7.0 million as of June 30, 2026.

Investor Verification Checklist

• Revenue Recognition Adjustments: Verify the sustainability of revenue streams given the significant negative adjustment to the Astellas Japan Agreement revenue in Q2 2026.
• Deconsolidation Gain: Confirm that the $30.9 million gain from the FibroGen Europe deconsolidation is a one-time non-operating event and not indicative of recurring profitability.
• Indemnification Exposure: Assess the potential for the $7.0 million accrued legal indemnification liability to increase based on the outcome of the SEC complaint against the former officer.
• RIFA Payment Cap: Review the terms of the NovaQuest financing to understand the cash flow impact of the payment cap (up to $125 million) and potential balloon payments in 2029/2031.
• Nasdaq Listing Status: Monitor the company's progress in regaining compliance with Nasdaq listing standards or the potential impact of a transfer to the Nasdaq Capital Market on stock liquidity.